欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
依据 EU GMP Annex 1 Manufacture of Sterile Medicinal Products 20220822
9.36 在制定APS计划时,应考虑如下: xii. Where campaign manufacturing occurs, such as in theuse of Barrier Technologies or manufacture of sterile active substances,consideration should be given to designing and performing the process simulationso that it simulates the risks associated with both the beginning and the endof the campaign and demonstrating that the campaign duration does not pose anyrisk. xii. 如果阶段式生产,例如使用屏障技术或生产无菌原料药,应考虑设计并执行工艺模拟以模拟与阶段开始和结束相关的风险,并证明阶段持续时间没有任何风险。
不理解:如果采用阶段性生产无菌原料药,应该怎么设计模拟方案,以模拟阶段开始和结束相关的风险?
大家有没有相关的经验,请指教!
|